Let's Make things Better
JNS: iNCOVACC— nasal vaccine against Covid-19 would be available in the market for the public from the fourth week of January. Bharat Biotech, Hyderabad-based Biotechnology Company said that the vaccine …
Intranasal Covid-19 vaccine, ‘iNCOVACC’ @ Rs 800 from January 23 Read More
JNS: The intranasal Covid-19 vaccine— iNCOVACC (BBV154), developed by Bharat Biotech, received approval from the ministry of health on Friday to be added to the vaccination programme as a booster …
iNCOVACC – Nasal spray vaccine gets nod as booster shot in adults Read More
JNS: The prices of Covid vaccine, COVISHIELD (Serum Institute) and COVAXIN (Bharat Biotech) have been slashed for private hospitals. The price of the Covishield vaccine has been reduced from 600 rupees …
Covishield, Covaxin price cuts to Rs 225 per dose for private hospitals Read More
JNS: The subject expert committee (SEC) of Drugs controller General of India (DCGI) has recommended that Hyderabad-based Bharat Biotech can conduct phase- three trials on its intranasal vaccine. The company …
Bharat Biotech gets nod for Phase 3 trials of intranasal vaccine Read More
JNS: World Health Organisation (WHO) granted approval to India’s first indigenous COVID-19 vaccine– Covaxin– for emergency use listing (EUL) for COVID-19 on Wednesday. The Technical Advisory Group of WHO, which …
Covaxin gets WHO approval for emergency use Read More
JNS: Covovax, another COVID-19 vaccine, being manufactured by Serum Institute of India, will be launched in October for adults and for children by the first quarter of 2022, said Adar Poonawalla, …
COVID jab for kids by first quarter of 2022: Poonawalla Read More JNS: The Central Government is mulling to increase the production of indigenously developed Covaxin— COVID-19 vaccine to approximately 1 million doses per month. Presently Bharat Biotech’s Covaxin production capacity is around …
Covaxin production to be increased 1mn per month under Atmanirbhar Bharat 3.0 Read More JNS: An expert panel on Tuesday recommended Covaxin (COVID-19 vaccine) for phase-2 and phase-3 clinical trial on younger population aged between 2 to 18 years, official sources said. The trial …
Covaxin gets approval for phase 2, 3 trials on 2-18 year-olds Read More JNS: Covaxin, has been found to neutralise Double Mutant or 617 variant of the Corona virus, said Dr Anthony Fauci, White House chief medical adviser and America’s top pandemic expert. This …
Covaxin found to neutralise 617 variant of Coronavirus Read More JNS: Covaxin, a coronavirus vaccine, developed in India by a Hyderabad-based company- Bharat Biotech, has reported overall interim clinical efficacy of 78 per cent, said Bharat Biotech and ICMR on …
Covaxin 100% effective against severe COVID-19: ICMR-Bharat Biotech Read More